Alpenglow

Alpenglow Biosciences, Inc. Sponsors Dinner Lecture titled "Decoding Immune Exclusion and Tumor Evasion in the TME", featuring Dr. Laura Dillon, PhD of Incendia Therapeutics

Retrieved on: 
Monday, October 30, 2023
Neoplasm, 3D, University of Paris, Pathology, MPH, Society for Immunotherapy of Cancer, Doctor of Philosophy, Phenotype, Research, Translational medicine, Alpenglow, SITC, Immunotherapy, Immune system, Dillon, DRS, Tumor microenvironment, Society, Therapy, TME, Immunology, Patient, SAN, Medical imaging, MD, Gas lighting, Cancer

The dinner lecture will take place on November 4th in San Diego's historic Gaslamp district.

Key Points: 
  • The dinner lecture will take place on November 4th in San Diego's historic Gaslamp district.
  • The evening will bring together thought leaders in industry and promises to be an informative and engaging exploration of the complexities of immune exclusion within the tumor microenvironment (TME) and its impact on cancer therapy.
  • In addition to Dr. Dillon, the panelists will include Professor Wolf H. Fridman, MD, PhD, Professor Emeritus of Immunology at University Paris Cité, Paris, France.
  • Dr. Fridman is a world-renowned expert on the role of the immune system in combating human tumors.

Alpenglow Biosciences presents the 3D Spatial Summit, an inaugural event for the field of 3D Spatial Biology to take place on September 21, 2023 in Cambridge, Massachusetts

Retrieved on: 
Tuesday, August 29, 2023
GE HealthCare, Therapy, Reder, Cone Health Women's Hospital, Cancer, Benveniste affair, Research, Harvard University, Harvard Medical School, Alpenglow, University Hospital Heidelberg, Patient, Cardiology, Diagnosis, Entrepreneurship, Hospital, Pharmacology, MPH, Summit, Laboratory, Medical imaging, Brigham, MD

CAMBRIDGE, Mass., Aug. 29, 2023 /PRNewswire/ -- Alpenglow Biosciences (Alpenglow), creators of an innovative end-to-end 3D spatial biology platform and suite of quantitative spatial statistical analysis tools, revealed their first annual 3D Spatial Summit scheduled for September 21, 2023 in Cambridge, Massachusetts.

Key Points: 
  • CAMBRIDGE, Mass., Aug. 29, 2023 /PRNewswire/ -- Alpenglow Biosciences (Alpenglow), creators of an innovative end-to-end 3D spatial biology platform and suite of quantitative spatial statistical analysis tools, revealed their first annual 3D Spatial Summit scheduled for September 21, 2023 in Cambridge, Massachusetts.
  • The inaugural Summit stands to become the premier event focused on the emerging field of 3D Spatial Biology.
  • The event will encompass essential tools, data processing, and data analytics capabilities necessary for extracting meaningful biological insights to support scientific discovery and the advancement of life-saving therapeutics.
  • The 3D Spatial Summit features an impressive speaker list comprising key opinion leaders from academia and industry to offer varied perspectives on the burgeoning application of 3D spatial biology in answering pivotal disease-related questions.

Alpenglow Biosciences awarded $1.6M grant to develop AI-enabled smart microscopy and 3D database of cancer biopsies

Retrieved on: 
Tuesday, August 1, 2023
Database, Reder, Workflow, Prostate cancer, Marie Cassidy, 3D, IGX, Pathology, Cancer, Research, Biomarker, CARE, NVIDIA, Machine learning, Algorithm, Inception, Artificial intelligence, Diagnosis, Growth, AI, MPH, Glass, GPU, Biopsy, Interstate 505, Medical imaging, Alpenglow, MD

"We are excited to continue to lead the field of 3D spatial biology and develop smart microscopy solutions to address cancer with this latest award," said Dr. Nicholas Reder, MD, MPH and CEO of Alpenglow Biosciences.

Key Points: 
  • "We are excited to continue to lead the field of 3D spatial biology and develop smart microscopy solutions to address cancer with this latest award," said Dr. Nicholas Reder, MD, MPH and CEO of Alpenglow Biosciences.
  • Alpenglow will use the award to further develop its smart microscopy platform which leverages its multi-resolution open top light sheet microscope.
  • "Our collaboration with Alpenglow Biosciences to further develop rapid and high throughput AI-enabled 3D imaging of entire cancer biopsies will provide pathologists with unprecedented tools to improve precision in cancer diagnostics," said Santa-Rosario.
  • "Alpenglow is poised to break the antiquated glass slide paradigm of pathology and usher in 3D spatial biology."

First U.S. CLIA Lab Implements Alpenglow's 3D Spatial Biology Platform Extending AI-Enabled Pathology to 3D

Retrieved on: 
Monday, October 17, 2022
CLIA, Risk, Therapy, Machine learning, LLC, Patient, Drug development, 3D, Tissue, MPH, Artificial intelligence, Technology, Alpenglow, Data management, Cancer research, Industry, AI, CEO, Prostate cancer, Marie Cassidy, Toxicology, Pathology, Solution, Algorithm, Medical imaging, MD

CorePlus was the first U.S. lab to implement artificial intelligence (AI) based tools for prostate cancer detection to support pathologists in providing accurate diagnoses and is leading the industry again with Alpenglow's AI-enabled 3D spatial biology platform.

Key Points: 
  • CorePlus was the first U.S. lab to implement artificial intelligence (AI) based tools for prostate cancer detection to support pathologists in providing accurate diagnoses and is leading the industry again with Alpenglow's AI-enabled 3D spatial biology platform.
  • "We are excited to be making this transformational leap forward in pathology," said Mariano de Socarraz, Founder and CEO at CorePlus.
  • Alpenglow's 3D offering includes an end-to-end platform solution for enabling whole-tissue digital imaging and analysis.
  • Their platform solution provides new spatial biology insights with greater accuracy by non-destructively digitizing entire tissues.

Earned Wage Access Provider ZayZoon Raises $25.5M to Bring Financial Flexibility and Empowerment to All Employees as a Standard Benefit

Retrieved on: 
Wednesday, August 3, 2022
CFO, Hopewell, Overalls, Financial technology, Choice Hotels International, Program, Burger King, Macdonald, St. Louis Fed Financial Stress Index, Solution, Engineering, GLOBE, Platinum Partners, Principal, ATB Financial, McDonald's, Health insurance, Creative industries, Alpenglow, Growth

Though almost all of the company's funding has originated from Canadian investors, the more than 3,000 businesses using ZayZoon to offer their employees quicker access to pay are located in the United States.

Key Points: 
  • Though almost all of the company's funding has originated from Canadian investors, the more than 3,000 businesses using ZayZoon to offer their employees quicker access to pay are located in the United States.
  • ZayZoon's core product Wages On-Demand gives employees access to wages that they have already earned but would otherwise have to wait until their next payday to receive.
  • Marcos Lopez, Principal of Alpenglow, says, "ZayZoon has proven the value it can bring to millions of employees and their employers through a unique distribution channel.
  • ZayZoon's on-demand access to wages helps reduce employee financial stress and materially improves workplace retention, resourcing and productivity.

Alpenglow Biosciences and CorePlus partner together to bring 3D Spatial Biology to clinical research and development

Retrieved on: 
Tuesday, July 19, 2022
CEO, CLIA, Solution, 3Deep, Therapy, Machine learning, Pathology, MPH, Toxicology, 3D, Drug development, Partnership, Biomarker, Intelligence, Tissue, Prostate cancer, Alpenglow, Medical imaging, MD

We are excited to partner with Alpenglow to incorporate their proprietary 3D spatial biology platform.

Key Points: 
  • We are excited to partner with Alpenglow to incorporate their proprietary 3D spatial biology platform.
  • Alpenglow has developed a leapfrog technology platform and leads the emerging field of 3D spatial biology with its 3Deep product suite.
  • Alpenglow and CorePlus aim to leverage 3D datasets to identify 3D biomarkers which could be used to improve patient selection for clinical trials, thereby reducing trial size and accelerating clinical development.
  • Alpenglow Biosciences is a privately held, venture-backed company focused on accelerating drug development and improving clinical diagnostics with AI-enabled 3D imaging technology.

Alpenglow Biosciences Unveils Fully Integrated "3Deep" Offering at BIO2022 Bringing AI-Powered, 3D Insights to Spatial Biology

Retrieved on: 
Tuesday, June 14, 2022
Cell, 3D, Nature Methods, Pathology, Alpenglow, Therapy, Multimedia, 3Deep, Gastrointestinal disease, Technology, Toxicology, Method, Drug development, Tissue, MPH, GeekWire, Medical imaging

Recently published in Nature Methods and GeekWire, presented at Digestive Disease Week

Key Points: 
  • Recently published in Nature Methods and GeekWire, presented at Digestive Disease Week
    SEATTLE, June 14, 2022 /PRNewswire/ -- Alpenglow Biosciences (Alpenglow), developers of an innovative end-to-end 3D spatial biology platform, has announced the unveiling of their fully integrated offering with proprietary tissue preparation, advanced imaging technology and AI-powered, cloud-based 3D analysis.
  • Inspired by first-hand experience, Alpenglow's cofounders developed the platform to transform pathology from traditional 2D microscopy to 3D insights.
  • The 3Deep name embodies the combination of stunning 3D tissue imaging with actionable insights only possible through AI-powered cloud computing.
  • Five of the top 10 pharma companies work with Alpenglow to accelerate development timelines, gain new insights, and improve therapeutic success.

Lightspeed Microscopy, Inc. Rebrands as Alpenglow Biosciences

Retrieved on: 
Tuesday, February 1, 2022
Pathology, Optical phenomena, Tissue, Alpenglow, Technology, News, Ownership, Drug development, Therapy, MPH, Biology, Toxicology, Multimedia, 2D, Pharmaceutical industry, Medical imaging, MD

SEATTLE, Feb. 1, 2022 /PRNewswire/ -- Lightspeed Microscopy, Inc., developers of an innovative end-to-end 3D spatial biology platform, has announced today that the company will begin operating under the name Alpenglow Biosciences, effective immediately.

Key Points: 
  • SEATTLE, Feb. 1, 2022 /PRNewswire/ -- Lightspeed Microscopy, Inc., developers of an innovative end-to-end 3D spatial biology platform, has announced today that the company will begin operating under the name Alpenglow Biosciences, effective immediately.
  • The name is an analogy to how Alpenglow Biosciences sheds new light on drug development and clinical diagnostics, moving research from conventional 2D slide-based pathology to digital and 3D.
  • To coincide with this name change, Alpenglow Biosciences (Alpenglow) revealed a new logo and website, www.alpenglowbiosciences.com , reflective of the new brand and visual identity.
  • Founded in 2018, Seattle-based Alpenglow Biosciences Inc. (Formerly Lightspeed Microscopy, Inc.) is a privately held, early-stage company focused on acceleratingdrug development and improving clinical diagnostics with AI-enabled, 3D imaging technology.

ALPENGLOW RAIL AND CC&L INFRASTRUCTURE ACQUIRE ORANGE RAIL TO EXPAND NORTH AMERICAN RAIL BUSINESS

Retrieved on: 
Thursday, January 6, 2022
Canadian National Railway facilities in Peel Region, Mount Alpenglow, GIS, Engineering, Transport, Pure, Coast, Acquisition, Land development, LJA, Rail transport by country, Cando Rail Services, Union Pacific Railroad, Biophysical environment, Union Pacific Corporation, BNSF, Water resources, Energy, CEO, CC, Construction, Public infrastructure, Private sector, Partnership, CSX, Surveying, Multimedia, Investment, Rail transport, Oil, Intermodal freight transport, Gulf Coast of the United States, Alpenglow

Orange Rail is a newly constructed rail terminal located in Orange, Texas with class 1 railroad access to both the Union Pacific and BNSF railroads.

Key Points: 
  • Orange Rail is a newly constructed rail terminal located in Orange, Texas with class 1 railroad access to both the Union Pacific and BNSF railroads.
  • Orange Rail sits on 130 acres of land in Orange, Texas, a growing hub for petrochemical manufacturing.
  • With the recent acquisitions of USA Rail Terminals and now Orange Rail, Alpenglow is quickly becoming one of the leading rail terminal owners and operators in North America.
  • "We are very excited to add Orange Rail to our USA Rail portfolio," said CEO of Alpenglow, Rich Montgomery.

CONNOR, CLARK & LUNN INFRASTRUCTURE AND ALPENGLOW EXPAND NORTH AMERICAN RAIL BUSINESS THROUGH ACQUISITION OF ORANGE RAIL

Retrieved on: 
Thursday, January 6, 2022
Transport, View, Acquisition, Growth, Rail transport by country, Union Pacific Railroad, Union Pacific Corporation, BNSF, CEO, CC, Partnership, Solution, Multimedia, Investment, Rail transport, Alpenglow

TORONTO, Jan. 6, 2022 /PRNewswire/ - Connor, Clark & Lunn Infrastructure (CC&L Infrastructure) and its partner, Alpenglow Rail LLC (Alpenglow), today announced the acquisition of Orange Rail Inc. (Orange Rail), a recently constructed rail terminal located in Orange, Texas.

Key Points: 
  • TORONTO, Jan. 6, 2022 /PRNewswire/ - Connor, Clark & Lunn Infrastructure (CC&L Infrastructure) and its partner, Alpenglow Rail LLC (Alpenglow), today announced the acquisition of Orange Rail Inc. (Orange Rail), a recently constructed rail terminal located in Orange, Texas.
  • The transaction further expands CC&L Infrastructure and Alpenglow's North American rail business, which now encompasses five rail assets in Canada and the United States.
  • "We are excited to add Orange Rail to our USA Rail portfolio," said CEO of Alpenglow, Rich Montgomery.
  • Alpenglow Rail develops and manages freight rail businesses and related transportation assets across North America.